Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

28,775 28,651 28,734 28,637

(1) Includes $- and $77 as additional research and development expense,

which represents an estimate of the net payable due to Novartis of

ANA975 research and development costs for the three months ended

September 30, 2008 and 2007, respectively. Includes ($47) and ($514)

as an offset in research and development expense, which represents an

estimate of the net reimbursement by Novartis of ANA975 research and

development costs for the nine months ended September 30, 2008 and

2007, respectively.

(2) Includes non-cash operating expenses of $738 and $1,392 determined in

accordance with Statement of Financial Accounts Standards No. 123(R),

"Share-Based Payment" (SFAS No. 123(R)) or approximately $0.03 and

$0.05 effect on basic and diluted net (loss) income per common share

for the three months ended September 30, 2008 and 2007, respectively.

Research and development expense and general and administrative

expense includes $326 and $412 of non-cash operating expenses

determined in accordance with SFAS No. 123(R) for the three months

ended September 30, 2008. Includes non-cash operating expenses of

$2,065 and $3,502 determined in accordance with SFAS No. 123(R) or

approximately $0.07 and $0.12 effect on basic and diluted net loss per

common share for the nine months ended September 30, 2008 and 2007,

respectively. Research and development expense and general and

administrative expense includes $949 and $1,116 of non-cash operating

expenses determined in accordance with SFAS No. 123(R) for the nine

months ended September 30, 2008.

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thousands)


'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... DUBLIN , May 20, 2015 Research and ... addition of the "Top Technologies in HW_Technical Insights" ... division of this report evaluated technology trends in the ... trends that are likely to have an impact in ... depth analysis of the top 10 health and wellness ...
(Date:5/20/2015)... The global genotyping market is expected ... forecast period of 2015 to 2020 to reach $17.0billion ... drug discovery and development process and to provide personalized ... to this,heavy investments by key manufacturers to offer advanced ... market growth. Browse 113 market data tables & 37 ...
(Date:5/20/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at The Jefferies 2015 Global Healthcare Conference in ... st , 2015 at 8:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jeff88/hae ... is a global healthcare company dedicated to providing innovative ...
(Date:5/20/2015)... PARK, North Carolina , 20. ... führende Unternehmen für klinische Logistik (Clinical ... für das Geschäftsjahr 2014, das am ... eingereicht. Das Unternehmen hat die Marktentwicklung ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
Breaking Biology Technology:Top Technologies in the Health and Wellness Industry 2015 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2
... Quanterix Corporation, a company enabling a new generation of ... ngle Mo lecule A rray (SiMoA ™ ... of its Prostate Specific Antigen (PSA) test, a fifth-generation ... predictor of five-year biochemical recurrence (BCR)-free survival following radical ...
... to make a highly efficient and yet cheaper silicon ... the cost of solar energy can be halved. ... Institute of Microelectronics (IME), the new thin-film silicon solar ... grade silicon. However it is able to generate electricity ...
... deCODE genetics today ... with Pfizer Inc., the objective of which is to ... to Systemic Lupus Erythematosis by utilizing deCODE,s expertise in ... extensive population and genetic resources, including DNA samples and ...
Cached Biology Technology:Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery 2Quanterix PSA Test Found to be a Reliable Predictor of Prostate Cancer Recurrence Following Surgery 3NTU and A*STAR Institute of Microelectronics develop cheaper yet efficient thin film solar cells 2deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis 2
(Date:5/19/2015)... , May 19, 2015  Technology is rapidly advancing, ... and in the cloud. Passwords and their management are ... OTP and standards-based specifications such as those developed by ... use of passwords presents for BYOD, COPE, IoT, and ... biometric identity protocol. In response to ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/7/2015)... 2015 Fingerprint Cards (FPC) ... FPC1035, FPC,s smallest touch fingerprint sensors to date.  ... for integration on the backside of the phone, ... possibilities to integrate touch fingerprint sensors in the ... possibilities for module manufacturers to customize the look ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... 28, 2009, Drinking cherry juice could help ease the ... Oregon Health & Science University presented at the American College ... showed people who drank tart cherry juice while training for ... than those who didn,t. Post-exercise pain can often indicate ...
... both milk feeding and in the weaning diet are ... have independent influences on body composition in early childhood, ... The Endocrine Society,s Journal of Clinical Endocrinology & ... suggest that the early environment may be a significant ...
... to alleviate diseases associated with menopause, she didn,t realize ... feeding hundreds of millions of people. The Northern ... the University of Arizona identified a nontoxic chemical technology ... which feast on crops intended for human consumption. ...
Cached Biology News:Is cherry juice a new 'sports drink?' 2Breastfeeding duration and weaning diet may shape child's body composition 2NAU discovery could help feed millions 2NAU discovery could help feed millions 3
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... Yellow crystalline solid. PROTECT FROM LIGHT. Useful in cell ... Purity: ≥98% by TLC. Soluble in DMSO ... of a 10 mM stock in DMSO is recommended. ... H 2 O with rapid mixing (e.g. 10 μl ...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: